BRIEF: Hengrui Pharma to raise up to $1.3 billion in Hong Kong IPO
Jiangsu Hengrui Pharmaceuticals Co. Ltd. (1276.HK; 600276.SH) launched its Hong Kong IPO on Thursday, aiming to sell 225 million shares at a price range of HK$41.45 to HK$44.05 per share, representing a roughly 25% discount to the price of its Shanghai-listed shares. The company will sell 5.5% of the shares to local retail investors. The sale could raise up to HK$9.9 billion ($1.3 billion), with subscriptions closing next Tuesday and trading commencing Friday.
The company specializes in therapies for areas spanning oncology, metabolic and cardiovascular diseases, immunology, respiratory disorders and neuroscience. Its portfolio includes over 110 commercialized drugs, featuring 19 new molecular entity innovative medicines and four other breakthrough therapies.
Its profit surged 48% year-on-year to 6.34 billion yuan in 2024. Its revenue climbed 20.1% year-on-year to 7.2 billion yuan in this year’s first quarter, with net income jumping 36.9% to 1.9 billion yuan.
Seven cornerstone investors have committed to buying a collective $530 million worth of Hengrui’s IPO shares, including Singapore’s GIC, Invesco Advisers, UBS Asset Management Singapore, Cordial Solar, Hillhouse Capital, Millennium Management and Oaktree Capital Management.
By Lau Chi Hang
To subscribe to Bamboo Works weekly free newsletter, click here
Related Articles
BRIEF: Hengrui executive to sell nearly 500,000 A-shares
BRIEF: Sanhua to raise up to $1 billion in Hong Kong IPO
RELATED ARTICLES
-
Hengrui Pharma accelerates bid for global brand status
600276.SHG -
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
BRIEF: Sany Heavy plans Hong Kong listing to raise up to $1.5 billion
600031.SHG
- BRIEF: Minieye IPO to raise up to $100 million in Hong Kong IPO
-
BRIEF: Guming to raise $220 million in Hong Kong IPO
1364.HK
-
BRIEF: CATL targets $4 billion in Hong Kong IPO, poised to become year’s top listing
300750.SHE
